Instructional Course - Requires Course Pass or Individual Course Ticket, Additional Registration Required
Steven Kaplan, MD
Director
Icahn School of Medicine at Mount Sinai
.jpg "Claus Roehrborn, MD photo")
Claus Roehrborn, MD
Department Head
UT Southwestern Medical Center
Alexis Te, MD
Weill Cornell Medical College
The diagnosis and management of Male Lower Urinary Tract Symptoms (mLUTS) and benign prostatic hyperplasia (BPH) has evolved and is reflected in the 2018 AUA BPH Guidelines with important and newly changing algorithms. This course with an outstanding faculty with first hand experience on all the relevant clinical trials is designed to review, discuss and develop a coherent diagnostic and treatment strategy for men with mLUTS utilizing these new Guidelines. More specifically, this will include discussion of the new diagnostic algorithms and the use of preoperative ultrasound and pressure flow studies. Medical therapy with both mono and combination therapy with agents such as alpha blockers, antimuscarinics, 5-alpha reductase inhibitors, PDE - 5 inhibitors will be reviewed. With the advancement of multiple new minimally invasive surgical options including prostatic urethral lift, convective water vapor therapy and prostate expanders and surgical options including Aquablation and updates on the role of electrosurgical and laser technique, Urologists need to be cognizant on how these new therapies align with the current Guidelines. In addition, how these agents dovetail with sexual function and testosterone replacement therapy will be highlighted. Finally, pharmaco economics and the impact of long term therapy as well as surgical outcomes will be debated.